The legal library articles of Indianapolis personal injury law firm Keller and Keller includes information on car accidents, truck accidents, motorcycle accidents, dog attacks, oral sodium phosphate lawsuits, defective prescription drugs, medical malpractice, Social Security disability, slip and fall accidents, and construction site accidents.
Indiana Accident Library

Contact us today for a free consultation.





Offices

Indianapolis Office:
2850 North Meridian Street
Indianapolis, IN 46208-4713
Phone: 317-926-1111
Fax: 317-926-1411

Toll Free: 800-253-5537

South Bend Office:
16658 Cleveland Rd
Granger, IN 46530-9186
Phone: 574-277-7773
Fax: 574-271-3337

Terre Haute Office:
1617 S 3rd St
Terre Haute, IN 47802-1013
Phone: 812-235-5600
Fax: 812-235-7800

Michigan Office:
814 Port Street
St. Joseph, MI 49085
Phone: 269-983-7333
Fax: 269-983-7377

New Mexico Office:
505 Marquette NW
Suite 1300
Albuquerque, NM 87102
Phone: 505-938-2300
Fax: 505-938-2301

Keller & Keller LLP on Facebook

LAMISIL

LAMISIL

What is Lamisil?

Lamisil, also known as Terbinafine, is in a class of medications called antifungals. It is prescribed to treat fungal infections of the fingernail and toenail and works by stopping the growth of the fungi.

Lamisil Concerns:

Rare cases of liver failure, some leading to death or liver transplant, have occurred with the use of Lamisil. Hepatoxicity may occur in patients with and without pre-existing liver disease. There have also been isolated reports of serious skin reactions

Important Signs and Symptoms:

Tell your doctor if any of these symptoms are severe or do not go away:
upset stomach, stomach pain, right upper abdominal pain
diarrhea
rash, hives, itching
change in taste or loss of taste

Call your doctor immediately if you experience any of these potentially serious side effects:
dark urine
pale feces
loss of appetite, vomiting, upset stomach that does not go away
extreme tiredness
severe skin rash that worsens
fever, sore throat and other signs of infection

FDA Warnings:

As of March 2001, the FDA had reviewed a number of possible Lamisil-associated cases of liver failure, including two that required liver transplants and another 11 ending in death. Given the possible serious risks, new labeling recommended that healthcare providers perform testing to confirm the diagnosis, prior to prescribing the drug.

On May 9, 2001 the FDA issued a Public Health Advisory to announce significant safety-related updates to the labeling of Lamisil tablets.





Disclaimer


WHAT'S MY CASE WORTH?

1+( )- - Click to call
Name:

Phone:

Email:

Tell us more:

Your contact information is strictly confidential. Review of your case by our legal team is free of cost. Submission does not constitute an attorney/client relationship.

No Fee Until You Win Your Case

Million Dollar AdvocatesLexis NexisSuper LawyersSamantha HouseBBB